Ling, Rod
Giles, Michelle
Searles, Andrew
Article History
Received: 25 February 2021
Accepted: 21 June 2022
First Online: 5 August 2022
Declarations
:
: The study was granted ethical approval through the Hunter New England Human Research Ethics Committee (reference no 16/10/19/5.09) and the Central Coast Human Research Ethics Committee (reference no 1016-097C).Individual patient consent was not required for the point prevalence data collection as all data collected was from already routinely collected inpatient clinical data and in line with routine quality control auditing. All clinical data collected during point prevalence was de-identified. This approach was approved by the abovementioned human research ethics committees, Hunter New England Human Research Ethics Committee and the Central Coast Human Research Ethics Committee.
: Not applicable
: All authors have completed the unified completing interest form (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.